q3 2013 investor conference call presentation slides

Q3 2013 ResultsInvestor Conference Call

October 31, 2013 / Marijn Dekkers, CEO

DisclaimerThis presentation may contain forward-looking statements based on currentassumptions and forecasts made by Bayer Group or subgroup management.

Various known and unknown risks, uncertainties and other factors could lead tomaterial differences between the actual future results, financial situation,development or performance of the company and the estimates given here.These factors include those discussed in Bayer’s public reports which areavailable on the Bayer website at www.bayer.com.

The company assumes no liability whatsoever to update these forward-lookingstatements or to conform them to future events or developments.

• Q3 2013 Investor Conference Call • Marijn Dekkers

Q3 2013 – Bayer Continues Encouraging Business Development

Ongoing strong performance of Life Sciences, MaterialScience level

with prior-year quarter

New pharma product sales exceeding expectations, full-year target

raised to >€1.4bn

Earnings significantly impacted by negative currency effects

Full-year 2013 Group outlook maintained although increasingly

ambitious


EBITin € million

+47%

1,221828

Salesin € million% currency & portfolio adj.

+6%

9,6439,661

EBITDAadjusted**in € million

+8%

1,9841,842

Core EPSin €

+9%

1.271.17

*Prior-year figures restated**before special items

Q3’13Q3’12* Q3’13Q3’12* Q3’13Q3’12* Q3’13Q3’12*

Q3 2013 –Encouraging Business Development


Q3 2013 – Regional Performance: Growth Led By Emerging Economies

Africa & Middle East

EasternEurope

Emerging Economies

EmergingEconomies¹

+9%

Others²+8%

USA+3%

Western Europe+5%

Q3 2013 Group Sales by Region

Group €9,643m; +6%

~1,400

+18%

~1,500

+1%

~400

+6%

~500

+11%

¹ Emerging economies include: Latin America, Asia w/o Japan, Australia,New Zealand, Africa and Middle East incl. Turkey, Eastern Europe

² Others = Japan, Australia, New Zealand, Canada³ Emerging Asia = Asia w/o Japan, Australia, New Zealand

In € million, ∆% yoy Fx adjusted

40%

9%31%

20%

Latin America

Emerging Asia³


Q3 2013 –Cash Flow And Net Debt Development

-€1.3bn

7.7

GCF oFCF

1,367

Invest-ments

514 1,214

∆y-o-y +36% -19%

NCF

1,728

-13% +6%June 30, 2013 Sep 30, 2013

9.0

Q3 2013 Cash Flow Net Debt DevelopmentCash Flow in € million, Net Debt in € billion


Q3 2013 – HealthCare: Organic GrowthDriven by New Products and Consumer Care

*before special items

Sales Earnings1

Pharma+3% (+11%)

ConsumerHealth

-3% (+3%)36%

HealthCare €4,742m; +1% (+7%)

2,8181,924

Price0%

Volume+8%

Fx-8%

Portfolio+1%

In € million, ∆% yoy, () = Fx & portf. adjusted

Q3‘12 Q3‘13 Q3‘12 Q3‘13

847915

484 477

+8%

-1%

1,3311,392 +5%

373 -1%

1,0061,048 +4%

633

371

Adj.EBITDA*

Adj.EBIT*

677 +7%

• Q3 2013 Investor Conference Call • Marijn Dekkers 1 Prior-year figures restated.

Sales Earnings1

Q3 2013 – CropScience: Good Start to the Season in Latin America

Crop Protection+6% (+14%)

Environmental Science+8% (+19%)

Seeds-30% (-30%)


CropScience €1,712m; +4% (+12%)

Price+3%

Volume+9%

Fx-8%

Portfolio+1%

1,504

Q3‘12 Q3‘13 Q3‘12 Q3‘13

197224 +14%

76

115 +51%

Adj.EBITDA*

Adj.EBIT*

14068

• Q3 2013 Investor Conference Call • Marijn Dekkers *before special items

1 Prior-year figures restated.

Sales Earnings1

Q3 2013 - MaterialScience: On Prior-Year Level

**CAS: Coatings, Adhesives, Specialties *** IO: Industrial Operations

CAS**-5% (+1%)


*before special items

MaterialScience €2,897m; -3% (+1%)

Price-1%

Volume+2%

Fx-4%

Portfolio0%

1,567673

IO***-9% (-7%)

Q3‘12 Q3‘13 Q3‘12 Q3‘13

Adj.EBITDA*

Adj.EBIT*

337 346 +3%

174186 +7%

486

171

• Q3 2013 Investor Conference Call • Marijn Dekkers 1 Prior-year figures restated.

Polyurethanes0% (+4%)

Polycarbonates-6% (-3%)

FY 2013 Group Outlook Maintained Although Increasingly Ambitious

20121 2013E

Sales €39.7bn +4-5% to~€40bn*

adj. EBITDA €8.3bn mid-single-digit % increase

Core EPS €5.30 high-single-digit % increase

Sales ∆ Fx and portfolio adjusted, EBITDA before special items

*Assuming average Fx rates of 9M 2013Outlook depends on specific planning assumptions as detailed in the Annual Report• Q3 2013 Investor Conference Call • Marijn Dekkers

1 2012 figures restated

Q3 2013 ResultsInvestor Conference Call

October 31, 2013 / Marijn Dekkers, CEO